Friedreich’s Ataxia (FRDA) is an autosomal recessive neurodegenerative disorder that is predominantly caused by a homozygous GAA repeat expansion mutation within intron 1 of the Frataxin (FXN) gene. This inherited disease causes nervous system damage and movement problems. To date, there is no cure or effective treatment for FRDA.
Efficacy studies performed by JAX® In Vivo Services for Friedreich’s Ataxia commonly employ molecular analysis of frataxin (FXN) expression levels (including ELISA or western blotting) in addition to clinical observations, body weight, echocardiography (ECG) and tissue/blood collection.
STOCK Fxnem2.1Lutzy Tg(FXN)YG8Pook/J (030930)
This model harbors a global knock-out of mouse frataxin and the human FXN YAC transgene small repeat YG8s (contracted integration to a single copy of the human FXN gene) with ~250-300 GAA trinucleotide sequence repeats (as of July 2017)
STOCK Fxnem2.1Lutzy Tg(FXN)YG8Pook/800J (030395)
These mice harbor a frataxin global knockout and a human transgene containing >800 GAA trinucleotide repeats.
B6.Cg-Fxnem2Lutzy Fxnem2.1Lutzy Tg(Ckmm-cre)5Khn/J (029720)
This model has a Cre-conditional frataxin allele, a frataxin global knockout allele and a cardiac/skeletal muscle-specific Cre recombinase transgene. This strain is widely used to study cardiac-specific frataxin depletion as a preclinical model to test enzyme replacement and gene therapies.
B6.Cg-Pvalbtm1(cre)Arbr Fxnem2Lutzy Fxnem2.1Lutzy/J (029721)
This triple mutant strain is designed to generate mice that are heterozygous for the frataxin null (global knock-out) allele with ablation of frataxin expression in parvalbumin-expressing neurons.
We use cookies to personalize our website and to analyze web traffic to improve the user experience. You may decline these cookies although certain areas of the site may not function without them. Please refer to our privacy policy for more information.